$0.73
+0.00 (+0.29%)
Open$0.72
Previous Close$0.72
Day High$0.75
Day Low$0.71
52W High$7.00
52W Low$0.53
Volume—
Avg Volume41.3K
Market Cap5.61M
P/E Ratio—
EPS$-1.26
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,324.6% upside
Current
$0.73
$0.73
Target
$10.33
$10.33
$6.34
$10.33 avg
$12.82
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.14M | 2.03M | 2.27M |
| Net Income | 217.1K | 264.7K | 291.2K |
| Profit Margin | 10.1% | 13.0% | 12.9% |
| EBITDA | 334.0K | 340.0K | 365.4K |
| Free Cash Flow | 225.5K | 170.6K | 157.9K |
| Rev Growth | +23.7% | +5.3% | -4.1% |
| Debt/Equity | 1.01 | 0.93 | 0.78 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |